Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Apatinib in Advanced Gastric/GEJ Cancer
NCT03813784Phase 3Completed
- Sponsor
- Hengrui
- Start
- Mar 2019
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Hengrui. Started Mar 2019; status: completed.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03813784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03813784.